Formula Diets May Produce Greater Weight Loss Than GLP-1 Peptide Drugs in Type 2 Diabetes, With Similar Long-Term Blood Sugar Control

Systematic review with PubMed searches through February 5, 2025. Fifty-four articles were included from 1,409 identified: 3 formula diet-based lifestyle interventions and 47 randomized, placebo-controlled pharmacological studies (GLP-1 RAs, GIP/GLP-1 combinations, SGLT-2 inhibitors). Primary and secondary outcomes were weight change (kg) and HbA1c change (%) using estimated treatment differences from intention-to-treat analyses. The total population was 87,871 patients (mean BMI 32.8 kg/m², age 60 years, 43% women).

GLP-1 receptor agonists and related peptide drugs are increasingly seen as the default treatment for obesity and type 2 diabetes, but they are expensive and require ongoing injections. This review provides evidence that structured formula diet programs — which are lower-cost and non-pharmacological — may actually produce better weight loss with equivalent long-term blood sugar control. This challenges the narrative that peptide drugs are the only effective option and highlights the importance of lifestyle medicine as a first-line approach.

As GLP-1 peptide drugs generate billions in annual revenue and transform diabetes and obesity treatment, questions about cost-effectiveness and necessity are becoming urgent. This review positions structured lifestyle intervention as a competitive — and potentially superior — alternative for weight management, while acknowledging that drug therapies may still be needed for glycemic control in some patients. The findings contribute to the evolving debate about when to prescribe medications versus invest in behavioral interventions.

The comparison is indirect — formula diet studies and drug trials had different designs, populations, and comparators (no head-to-head randomized trials). Only 3 formula diet programs were included versus 47 drug studies, creating an asymmetric comparison. Formula diet adherence in real-world settings may differ from supervised study conditions. Weight regain after formula diet discontinuation was not specifically addressed. The drug comparison combines GLP-1 RAs, GIP/GLP-1 combinations, and SGLT-2 inhibitors with different mechanisms, which may mask variability between drug classes.